Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decrease in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totaling 4,060,180 shares, a drop of 52.3% from the April 30th total of 8,509,923 shares. Based on an average daily volume of 3,052,240 shares, the days-to-cover ratio is currently 1.3 days. Currently, 12.1% of the shares of the company are short sold.

Theriva Biologics Trading Up 1.4%

Shares of TOVX stock opened at $0.29 on Wednesday. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $0.86. The stock has a market capitalization of $9.65 million, a P/E ratio of -0.01 and a beta of 1.10. The firm’s 50 day moving average is $0.29 and its 200 day moving average is $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Theriva Biologics has a consensus rating of “Buy” and a consensus target price of $1.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC grew its holdings in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.